Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4

被引:0
作者
Oskola, E. V. [1 ]
Shubina, A. T. [1 ]
Karpov, Yu. A. [1 ]
机构
[1] Inst Clin Cardiol, Moscow, Russia
关键词
angioprotection; type 2 diabetes mellitus; dipeptidyl peptidase-4 inhibitors; incretins; DEPENDENT INSULINOTROPIC POLYPEPTIDE; TYPE-2; DIABETES-MELLITUS; LIPOPROTEIN-LIPASE ACTIVITY; GLUCAGON-LIKE PEPTIDE-1; NITRIC-OXIDE RELEASE; CARDIOVASCULAR SAFETY; ENDOTHELIAL FUNCTION; GLYCEMIC CONTROL; ADIPOSE-TISSUE; SITAGLIPTIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) is a major health problem in all developed countries. It contributes to the development of atherosclerosis and increases the risk of cardiovascular events so blood glucose level correction is essential to preventing these complications. The relatively new and promising class of anti-diabetic drugs is dipeptidyl peptidase-4 inhibitors. By improving carbohydrate metabolism, they have angioprotective effects, such as anti-inflammatory and anti-atherosclerotic ones, including atherosclerotic plaque stabilization, improve endothelial function, lower blood pressure, and reduce the severity of albuminuria, which may have clinical implications for the prevention of macrovascular complications of type 2 DM.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 50 条
[21]   Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience [J].
Derosa, Giuseppe ;
Maffioli, Pamela .
DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 (04) :350-364
[22]   Pharmacology of Dipeptidyl Peptidase-4 Inhibitors Similarities and Differences [J].
Baetta, Roberta ;
Corsini, Alberto .
DRUGS, 2011, 71 (11) :1441-1467
[23]   Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes [J].
Ahren, Bo .
EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (04) :593-607
[24]   The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors [J].
Avogaro, Angelo ;
Fadini, Gian Paolo .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (08) :1686-1695
[25]   Synthesis of dipeptidyl peptidase-4 inhibitors: a brief overview [J].
Mulakayala, Naveen ;
Reddy, Upendar C. H. ;
Iqbal, Javed ;
Pal, Manojit .
TETRAHEDRON, 2010, 66 (27-28) :4919-4938
[26]   Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence [J].
van Genugten, R. E. ;
van Raalte, D. H. ;
Diamant, M. .
DIABETES OBESITY & METABOLISM, 2012, 14 (02) :101-111
[27]   Dipeptidyl peptidase-4 inhibitor approaches [J].
Bloomgarden, Zachary .
JOURNAL OF DIABETES, 2017, 9 (01) :5-7
[28]   Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure: Regression to the Truth? [J].
Zannad, Faiez ;
Rossignol, Patrick .
CIRCULATION, 2019, 139 (03) :362-365
[29]   Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes [J].
Scheen, Andre J. .
POSTGRADUATE MEDICINE, 2013, 125 (03) :7-20
[30]   Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A New Oral Alternative [J].
Kintscher, U. .
DIABETES STOFFWECHSEL UND HERZ, 2009, 18 (03) :169-175